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Background: We previously observed that the TGFbeta-Par6 pathway mediates loss of polarity and apoptosis in
NMuMG cells. Here we investigate the contribution of Par6 versus TGFbeta receptor I activation to TGFbeta-induced
apoptosis in association with changes in apico-basal polarity. We focus on the effect of Par6 activation on
alpha6beta4 integrin expression and localization, and Nuclear Factor-kappaB (p65/RelA) activation, previously shown
to mediate polarity-dependent cell survival.
Methods: Using immunoblotting and/or immunofluorescence we investigated the effect of TGFbeta1 on apoptosis,
alpha6, beta4 and beta1 integrin expression/localization, and p65/RelA phosphorylation/localization in monolayer
and three-dimensional (3D) cultures of NMuMG cells with an overactive or inactive Par6 pathway. Results were
quantified by band densitometry or as percent of 3D structures displaying a phenotype. Differences among means
were compared by two-way ANOVA.
Results: Blocking Par6 activation inhibits TGFbeta-induced apoptosis. Par6 overactivation enhances TGFbeta-induced
apoptosis, notably after 6-day exposure to TGFbeta (p < 0.001), a time when parental NMuMG cells no longer respond
to TGFbeta apoptotic stimuli. 48-hour TGFbeta treatment reduced beta4 integrin levels in NMuMG monolayers and
significantly reduced the basal localization of alpha6 (p < 0.001) and beta4 (p < 0.001) integrin in NMuMG 3D structures,
which was dependent on both Par6 and TGFbeta receptor I activation and paralleled apoptotic response. After 6-day
exposure to TGFbeta, Par6-dependent changes to beta4 integrin were no longer apparent, but there was reduced
phosphorylation of p65/RelA (p < 0.001) only in Par6 overexpressing cells. Differences in p65/RelA localization were not
observed among the different cell lines after 48-hour TGFbeta exposure.
Conclusions: Par6 and TGFbeta receptor I activation are both necessary for TGFbeta-induced apoptosis in NMuMG
cells. Importantly, Par6 overexpression enhances the sensitivity of NMuMG to TGFbeta-induced apoptosis, notably upon
prolonged exposure to this growth factor, when NMuMG parental cells are usually apoptosis-resistant. Thus,
endogenous Par6 level might be important in determining whether TGFbeta will function as either a pro-apoptotic or
pro-survival factor in breast cancer, and potentially aid in predicting patient’s prognosis and therapy response.
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Transforming growth factor-beta (TGFβ) mediates mam-
mary gland morphogenesis [1], and is known to play dual
roles in breast cancer progression, by acting as a tumor
suppressor in normal or pre-malignant cells, while pro-
moting tumor progression in malignant cells [2,3]. TGFβ’s
tumor suppressor function is in part mediated by its
capacity to induce apoptosis, while its role in tumor
progression has been linked to its ability to induce
epithelial-to-mesenchymal transition (EMT), which pro-
motes local invasion and metastasis [4,5].
TGFβ signals via a hetero-tetramer receptor formed by
two TGFβ receptor I (TβRI) and two TGFβ receptor II
(TβRII) units [6,7]. The canonical TGFβ/Activin signal-
ing pathway is initiated by TGFβ binding to TβRII,
which facilitates the formation of a complex with TβRI.
Once in the complex, TβRII (a constitutively active kin-
ase) phosphorylates and activates TβRI, which in turn
recruits the receptor-activated Smads (R-Smads), Smad2
and Smad3. This leads to Smad 2/3 phosphorylation and
activation by TβRI, enabling them to form a complex
with the co-Smad, Smad4. The Smad2/3-Smad4 complex
then translocates to the nucleus, where in cooperation
with other transcription factors, co-activators, and co-
repressors, modulates gene expression [8]. Apart from
Smad signaling, TGFβ activates non-canonical pathways,
including PI3K/Akt, NF-κB, Erk, p38 MAPK, JNK, FAK
and the Par6 pathway, among others [9,10].
Partitioning-defective 6 (Par6) is part of the Par polarity
complex that localizes to the tight junction (TJ) and is
comprised of the three highly conserved proteins Par6,
Par 3 and atypical protein kinase C (aPKC). In mammalian
cells, this complex participates in the establishment of
apico-basal polarity, directional migration, EMT (reviewed
in [11]) and cell division [12]. Misregulation in expression
and/or activity of Par complex components has been
shown to promote breast cancer progression [13-16]. In
epithelial mammary cells, Par6 is constitutively associated
with TβRI at the TJ and is directly phosphorylated (at
Ser345) and activated by TβRII in response to TGFβ. This
is essential for TGFβ-induced EMT and facilitates metas-
tasis [17,18]. The TGFβ-Par6 pathway promotes EMT via
recruitment of the ubiquitin ligase Smurf1 to the TJ, lead-
ing to RhoA ubiquitination and its proteasomal degrad-
ation at the TJ site [17], the destabilization and dissolution
of the TJ, and ultimately the rearrangement of the actin
cytoskeleton [17,18]. Conversely, we also found Par6 to
mediate TGFβ-induced apoptosis, one of TGFβ’s tumor
suppressive effects [18]. The mechanisms of TGFβ-
induced apoptosis are not fully understood, although tran-
scriptional changes in pro- and anti-apoptotic proteins
mediated by the Smad family [19], and Smad independent
activation of TRAF6 and its downstream targets JNK and
p38 MAPK [20,21] are well documented.Here we further investigate the involvement of the
TGFβ-Par6 pathway in apoptosis by focusing on its role
in disrupting apico-basal polarity [17]. Growing evidence
suggests that cell polarity modulates sensitivity to apop-
tosis. In particular, integrins, cell adhesion molecules
that regulate cellular response to the extracellular matrix
(ECM), were shown to promote cell polarity and confer
resistance to apoptosis [22]. Specifically, the ligation
of integrin α6β4 to reconstituted basement membrane
was required for the polarization of mammary epithe-
lial cells in three-dimensional (3D) culture [22], where
cells display an apico-basal polarity similar to the
mammary acinus in vivo [23]. This was shown to be
dependent upon integrin ligation to laminin, which
also conferred resistance to apoptosis-inducing stimuli
via activation of NF-κB [22]. Autocrine laminin-5
ligation of α6β4 integrin was later shown to facilitate
anchorage-independent survival of transformed mam-
mary cells via activation of a Rac-NF-κB signaling
cascade [24]. In agreement with the role of TGFβ in
disrupting apical-basal polarity, TGFβ stimulation of
mammary epithelial cells was shown to cause down-
regulation of β4 integrin, and modulate the expres-
sion of many other integrins including α2, α5, β5, and
α6 [25]. However, the impact that canonical and/or
Par6 signaling has on apical-basal polarity and how it
relates to integrin expression, integrin localization and
apoptotic response to TGFβ has not been formerly
addressed.
Here we used Namru murine mammary gland (NMuMG)
epithelial cells displaying an overactive (Par6/wt) or in-
active (Par6/S345A) Par6 pathway, or lacking β4 integrin,
to investigate whether the TGFβ-Par6 pathway mediates
changes in α6β4 integrin expression and/or localization,
and whether these changes associate with loss of polarity
and apoptotic response. We use NMuMG because we
consider this to be –despite of its common description
as “normal”– the best characterized cell line that is rep-
resentative of early stage (i.e., pre-malignancy) mam-
mary transformation. Unlike other mammary cell lines
available, TGFβ is able to induce both apoptosis and
EMT in NMuMG cells [17,18,26], with apoptosis occur-
ring only at earlier TGFβ exposure times (up to 5 days)
in a susceptible fraction of the cells, while EMT pre-
dominates at later exposure times (over 5 days) [26]
in the remaining, apoptosis-resistant population. This
unique feature makes NMuMG cells an invaluable
model to elucidate the specific signaling events that
favor apoptosis versus cell survival/EMT in response to
TGFβ. Important implications of addressing this ques-
tion include the exciting possibility of potentiating cell
death in advanced breast cancer subtypes, where TGFβ-
induced EMT might play a role in metastatic spread and
therapy resistance [27].
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Apoptosis of NMuMG treated with TGFβ1
We have previously shown that blocking Par6 activation
suppresses loss of polarity and reduces apoptosis in re-
sponse to TGFβ in 3D acini-like structures of NMuMG
cells [18]. To confirm this, and to determine whether
this phenomenon is restricted to cells growing as 3D
structures, we evaluated apoptotic response to TGFβ1 in
monolayers of NMuMG cells. For this purpose, we com-
pared apoptotic response in NMuMG cells expressing
the wild type form of Par6 (Par6/wt), which have been
shown to display a constitutively active Par6 pathway
[18], to NMuMG cells expressing a dominant negative
form of Par6 (Par6/S345A), where Par6 activation is
constitutively blocked [17,18].
Importantly, in preliminary experiments comparing
the response of empty vector-expressing clonal lines to
parental NMuMG cells (to ensure lack of bias due to the
vector system used to express Par6) we came across an
empty vector-expressing variant line (NMuMG-V1) that
showed increased basal apoptosis, displayed a rapid
EMT response to TGFβ and did not form polarized
structures in 3D (Ozdamar and Viloria-Petit, unpublished
observations). Since β4 integrin expression is required for
the formation of polarized acini-like structures and to me-
diate cell survival in mammary epithelium [22] we exam-
ined the expression of β4 integrin mRNA in NMuMG-V1
as compared to Parental, Par6/wt and Par6/S345A cells
with and without the addition of TGFβ, using qRT-PCR.
We found the NMuMG-V1 cell line to be deficient in β4
integrin expression (Figure 1). It was also observed that
















Figure 1 β4 integrin expression in NMuMG cell variants.
Subconfluent NMuMG monolayers were treated with TGFβ1 (5 ng/ml)
for 48 hours. Total RNA was extracted and reverse-transcribed to cDNA.
β4 integrin was determined using quantitative real-time polymerase
chain reaction (qRT-PCR) and normalized to GAPDH levels. Graph
depicts the average fold change (± SEM) in Par6-expressing (Par6/wt and
Par6/S345A) and an empty vector-expressing clonal variant of NMuMG
cells (NMuMG-V1; later referred to as β4 null) relative to parental cells;
n = 3 for biological replicates and n = 3 for technical replicates. Two-way
ANOVA for all cell lines and treatments was significant (p < 0.0001 and
p = 0.0060, respectively). Bonferroni post test compared differences
between control and treatment for each cell line, ***p <0.0001.β4 integrin as compared to parental cells and that TGFβ
treatment downregulated β4 integrin mRNA expression
in parental and Par6/wt cells but not in Par6/S345A
(Figure 1). Based on these results we sought to compare
the apoptotic response of all cell lines to TGFβ, and
whether or not it correlated with the level of β4 integrin
expressed by the cell lines. From here on we refer to
NMuMG-V1 as “β4 null” cells, given their lack of β4 in-
tegrin expression.
Cell monolayers were treated with 5 ng/ml TGFβ1 for
48 and 144 hours (i.e., 2 and 6 days, respectively). The
48 hour time point was chosen based on our previous
observation of this being a time at which apoptotic re-
sponse can be detected in NMuMG cells [18]; while the
144 hours/6 days time point was chosen because
NMuMG parental cells no longer undergo apoptosis at
this time point [26]. To additionally investigate the rela-
tionship between the Par6 and the TβRI-activated ca-
nonical Smad pathway (i.e., the TGFβ/Activin pathway
[28]) and their individual contribution to TGFβ-induced
apoptosis, the TβRI inhibitor SB-431542 [29], known to
block the TGFβ/Activin pathway and subsequent Smad2/
3 activation [28] was included alone or in combination
with TGFβ1. Relative caspase-3 cleavage (cleaved caspase-
3 expression/caspase-3 expression) was determined to as-
sess apoptosis.
Caspase 3 cleavage under basal conditions (in the ab-
sence of TGFβ1 and SB-431542) was higher in β4 null
cells and lowest in Par6/wt cells at both time points
tested (Figure 2A and C). Following 48 hours of TGFβ
treatment, caspase-3 cleavage was increased in the par-
ental NMuMG, β4 null, and Par6/wt cell lines as com-
pared to basal levels, but not in Par6/S345A cells
(Figure 2A,B). However, this effect was only significant
(p < 0.001) in the Par6/wt cells (Figure 2B), suggesting
that cells with an overactive Par6 pathway are more sen-
sitive to TGFβ-induced apoptosis. There was an attenu-
ated (two-fold lower) apoptotic response in the β4-null
cell line compared to parental NMuMG cells, but it did
not translate into a statistically significant difference be-
tween these two cell lines (Figure 2B). Examination of
PARP cleavage as an additional indicator of apoptosis
confirmed higher apoptotic response to TGFβ in Par6/
wt cells at the 48-hour time point (Figure 2A).
Following TGFβ1 treatment for 144 hours, there was
little to no detectable caspase-3 cleavage in the parental,
β4 null, or Par6/S345A cells, while in the Par6/wt cells,
there was a significant (p < 0.001) increase in caspase-3
cleavage (Figure 2C,D). SB-431542 inhibited the cleav-
age of caspase-3 (Figure 2A-D). These results indicate
that both Par6 and TβRI activation are required for
TGFβ-induced apoptosis. The lack of detectable increase
in caspase-3 cleavage in the Par6/S345A expressing cell
line suggests that Par6 activation, and not just Par6
Figure 2 Par6 overactivity sensitizes NMuMG cells to TGFβ-
induced apoptosis. Subconfluent monolayers of the indicated
NMuMG–derived cell lines were treated with control media (DMSO
alone), TGFβ1 (TGFβ; 5 ng/ml), the TβRI/SMAD inhibitor SB-431542 (SB)
or TGFβ + SB. The level of cleaved caspase-3 was determined as a
read-out of apoptosis after 48 hours (A, B) or 144 hours (C, D)
treatment. A and C show levels of cleaved caspase-3 (CC3), uncleaved
caspase-3 (C3) and α-tubulin (loading control) as determined by
immunoblotting. Cleaved PARP (cPARP) in A served as an additional
read-out of apoptosis. Graph in B and D represents the average relative
caspase-3 cleavage calculated by band densitometry for 3 independent
experiments. Relative C3 cleavage was calculated as the ratio of CC3 to
C3. The value for DMSO control was set to 1 for each cell line. Two-way
ANOVA for all cell lines and treatments was significant (p < 0.001).
Bonferroni post test compared differences between control and
treatment for each cell line, **p < 0.001.
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ther, both basal and TGFβ−induced apoptosis after
48 hours treatment (Figure 2A,B) correlate with relative
β4 integrin mRNA expression at the same time point
(Figure 1).Effect of TGFβ on apoptosis in NMuMG three-dimensional
structures
To confirm the effect of Par6 activation on TGFβ-induced
apoptosis in conditions favoring the establishment of
proper apico-basal polarity, we assessed the expression
of cleaved/activated caspase-3 and cleaved/activated cas-
pase-9 (an initiator of the intrinsic apoptotic pathway
in response to TGFβ [30]), via immunofluorescence (IF)
staining of NMuMG 3D structures grown on laminin-rich
ECM (Figures 3, 4 and 5). The confocal images shown
in Figures 3A, 4A and 5A show the most common
phenotype observed for each cell line and treatment,
while Figures 3B, 4B and 5B show plots that compare
the average percentage of apoptotic structures for each
cell line and treatment.
After treatment with DMSO alone (basal conditions)
for 48 hours, Parental and Par6/S345A cells were generally
acini-like, with obvious hollow-lumens and apical-lateral
ZO-1, while β4 null and Par6/wt cells lacked lumens
(Figures 3A, 4A). An average of 96% of the structures
formed by β4 null cells were caspase-3 positive under
basal conditions (Figure 3A,B), while for the other three
cell lines only 12-39% of the structures were caspase-3
positive (Figure 3B). When caspase-3 and -9 activation
were compared in these three cell lines, Par6/wt cells
showed the highest basal percentage of caspase-3 (39%)
and -9 (14%) positive cells (Figures 3B, 4B). Following
TGFβ treatment, ≈ 60% of parental NMuMG structures
lost polarity (evidenced by both, lack of a lumen and of
apical-lateral ZO-1 staining) and showed immunoreactiv-
ity for both cleaved caspase-3 and -9. Par6/wt structures
showed a similar apoptotic response to TGFβ (Figures 3
and 4). In contrast, the majority of Par6/S345A cells (≈
75%) did not lose polarity in response to TGFβ treatment
and showed no detectable levels of cleaved caspase-3 or -9
expression (Figures 3A, 3B, 4A and 4B). Statistical analysis
for caspase-9 cleavage showed a significant increase (p <
0.001) in the number of parental and Par6/wt, but not
Par6/S345A structures undergoing apoptosis in response
to TGFβ treatment for 48 hours (Figure 4B). This effect
was abrogated by SB-431542 treatment, indicating the re-
quirement of both TβRI and Par6 activation for the loss of
polarity and induction of apoptosis caused by TGFβ.
Caspase-3 cleavage immunostaining after a 144-hour
TGFβ treatment, showed a 2-fold lower average of positive
structures as compared to the 48-hour time point in par-
ental cells (34% versus 62%; Figure 5B versus 3B), while
the average of positive Par6/wt and Par6/S345A structures
was similar at these two time points (66% versus 70% for
Par6/wt and 30% versus 27% for Par6/345A at the 144-
and 48-hour time points, respectively). Of note, the aver-
age percent of apoptotic structures at the 144-hour time
point was at least 2-fold higher for Par6/wt as compared
to the other two cell lines under all treatments, except for
Figure 3 TGFβ-induced caspase-3 cleavage requires both Par6 and TβRI activation in NMuMG 3D structures. 12-day old 3D structures of
the indicated NMuMG-derived cell lines were treated with control media (DMSO alone), TGFβ1 (TGFβ), the TβRI/Smad2 inhibitor SB-431542 (SB)
or TGFβ + SB for 48 hours, fixed and immunostained for cleaved caspase-3 (CC3, green). Dapi was used to visualize the nuclei. A. Confocal images
of representative structures for each cell line and treatment. Scale bar = 20 μm. B. Average percentage of apoptotic structures and error bars (SD)
were calculated for n = 3 technical replicates within one experiment.
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of apoptosis in Parental cells, but was less effective at
doing so in Par6/wt and Par6/S345A cells. β4 null cells
were not analyzed at this time point because individual
3D structures were no longer identified. Taken together
with our immunoblotting analysis, these results suggest
that the Par6 pathway cooperates with the TGFβ/Activin
signaling pathway to mediate apoptotic response to TGFβ,
and Par6/wt overexpression promotes apoptosis upon
prolonged exposure to TGFβ in NMuMG cells under both
2D and 3D culture conditions.
Changes in integrin and E-cadherin expression in NMuMG
following TGFβ treatment
To investigate whether changes in the expression of pro-
survival integrins correlate with TGFβ-induced apoptosisand whether the Par6 or TGFβ/Activin pathway modulate
these changes, we evaluated the expression of integrin α3,
β1 and β4 following treatment for 48 or 144 hours with
TGFβ1, SB-431542, or both in combination. The expres-
sion of α3 integrin was not significantly altered following
TGFβ treatment at either of the two time points (data
not shown). β1 integrin expression was induced by
TGFβ at both 48 and 144 hours treatment (see 130 kDa
band; Figure 6A,B). This induction was similar across all
four NMuMG cell lines tested and was inhibited by SB-
431542 treatment. Conversely, as previously observed at
the mRNA level (Figure 1), TGFβ treatment down-
regulated the expression of β4 integrin in NMuMG paren-
tal and Par6/wt cells following the 48-hour treatment,
although neither difference was found to be statistically
significant (Figure 6A and C, left graph). This down-
Figure 4 TGFβ-induced caspase-9 cleavage requires both Par6 and TβRI activation in NMuMG 3D structures. 12-day old 3D structures of
the indicated NMuMG-derived cell lines were treated with control media (DMSO alone), TGFβ1 (TGFβ), the TβRI/Smad2 inhibitor SB-431542 (SB)
or TGFβ + SB for 48 hours, fixed and immunostained for zonula occludens-1 (ZO-1, green) and cleaved caspase-9 (CC9, red). Dapi was used to
visualize the nuclei. A. Confocal images show representative structures for each given cell line and treatment. Scale bar = 20 μm. Arrow = apoptotic
nuclei. B. Average percentage of apoptotic structures was calculated per each cell type and treatment, with n = 3 for biological replicates. Two-way
ANOVA for all cell lines and treatments was significant (p < 0.001). Bonferroni post test compared differences between control and treatment for each
cell line, **p < 0.001.
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was not observed in Par6/S345A cells at this time point
(Figure 6A and C, left graph). Following 144-hour TGFβ
stimulation, β4 integrin expression was significantly de-
creased only in the parental cells (p < 0.001), while the
decrease was non-significant in both Par6/wt and Par6/
S345A cells (Figure 6B and C, right graph). Similarly to
the 48-hour time point, SB-431542 treatment restored
β4 integrin levels back to basal, particularly in parental
and Par6/wt cells (Figure 6B and C, right graph).
To test whether changes in integrin expression corre-
lated with changes in polarity proteins, we also exam-
ined E-cadherin expression, a marker of the adherens
junctions (AJ). There was a slight decrease in E-cadherin
following 48 hours TGFβ treatment in parental and
Par6/wt cells (Figure 6A), which became more apparentat the 144 hours time point (Figure 6B). This effect was
not seen in Par6/S345A (Figure 6A,B), in agreement
with their reported inability to undergo loss of polarity
and EMT in response to TGFβ [17,18]. β4 null cells
expressed significantly lower basal levels of E-cadherin
as compared to all other cell lines, and there was a pro-
nounced decrease in E-cadherin expression in the β4
null cells following 48 hours and 144 hours of TGFβ
treatment (Figure 6A,B). The decrease in E-cadherin ex-
pression observed in Parental, Par6/wt and β4 null cells
following TGFβ treatment for 48 or 144 hours was ab-
rogated upon inhibition of TβRI/Smad activation by
SB-431542 treatment (compare E-cad and pSmad2 in
Figure 6A and B). There was significantly higher TGFβ-
induced Smad2 activation in β4 null cells as compared
to all other cells. Taken together, these results suggest
Figure 5 Par6/wt-overexpressing cells maintain a high apoptosis response to TGFβ in long-term treated 3D culture. 12–day old 3D
structures of the indicated NMuMG-derived cell lines were treated with control media (DMSO alone), TGFβ1 (TGFβ), the TβRI/Smad2 inhibitor
SB-431542 (SB) or TGFβ + SB for 144 hours, fixed and immunostained for cleaved caspase-3 (CC3, green). Dapi was used to visualize the nuclei.
A. Confocal images show representative structures for each given cell line and treatment. Scale bar = 20 μm. B. Average percentage of apoptotic
structures and error bars (SD) were calculated for n = 3 technical replicates within one experiment.
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of TβRI, and to a lesser extend on Par6 activation, but
only at the 48 hours time point. Both TβRI and Par6
activation are required for E-cadherin downregulation
following TGFβ stimulation, in agreement with the
demonstrated role of the TβRI/Activin and Par6 path-
ways in TGFβ-induced EMT [3]. The pronounced β4
downregulation observed in parental cells at the
144 hours time point, when these cells do not undergo
significant apoptosis, suggests that a reduction in theexpression level of β4 integrin is not likely to mediate
apoptosis at this time point.
Effect of TGFβ on α6β4 integrin localization in NMuMG
three-dimensional structures
Enriched integrin expression at the cell’s basal site is a
hallmark of apico-basal polarity and integrin α6β4 binding
to laminin at the ECM was previously shown to signal
survival in polarized, acini-like structures of mammary
Figure 6 TGFβ modulates integrin β4 expression in a Par6- and TβRI-dependent manner. Subconfluent monolayers of the indicated
NMuMG-derived cell lines were treated for 48 hours (A) or 144 hours (B) with control media (DMSO alone), TGFβ1 (TGFβ, 5 ng/ml), the TβRI/
Smad2 inhibitor SB-431542 (SB, 10 μM) or TGFβ + SB. A and B show levels of β4 integrin (β4), E-cadherin (E-cad), β1 integrin (β1), phospho-Smad2
(pSmad2, Ser465/467) and Smad2 as determined by immunoblotting; α-tubulin was used as loading control. C. Graphs represent the average relative
β4 integrin expression after 48-hour (left) or 144-hour (right) treatment as determined by band densitometry for n = 3 independent experiments.
Relative β4 integrin expression was calculated as the ratio of β4 integrin to α-tubulin. The value for DMSO control was set to 1 for each cell line.
Two-way ANOVA for all cell lines and treatments was significant (p< 0.05) for the 144-hour treatment. Bonferroni post test compared differences between
control and treatment for each cell line, **p < 0.001.
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pathway could negatively impact survival signaling by
promoting de-localization of integrins away from the
basal site, we examined the expression of integrins α6β4
in 3D structures of Parental, Par6/wt and Par6/S345A
NMuMG cells.
Both β4 and α6 integrin localize basally in mature, 14-day
old parental NMuMG, Par6/wt, and Par6/S345A three-dimensional acini-like structures (Figures 7 and 8). 48-hour
TGFβ treatment significantly decreased (p < 0.001) the
number of parental structures expressing basal β4 integrin
(Figure 7A,B), and the number of parental and Par6/wt
structures expressing basal α6 integrin (Figure 8A,B). The
decrease in basal expression of both α6 and β4 integrin
observed in the parental structures, and of α6 integrin in
the Par6/wt structures was abrogated by SB-431542
Figure 7 Par6 and TβRI activation mediate TGFβ-induced loss of basal β4 integrin expression in NMuMG 3D structures. 12-day old 3D
cultures of the indicated NMuMG-derived cell lines were treated with control media (DMSO alone), TGFβ1 (TGFβ), the TβRI inhibitor SB-431542
(SB) or TGFβ + SB for 48 hours, fixed and immunostained for β4 integrin (green). Dapi was used to visualize the nuclei (blue). A. Confocal images
show representative structures for each given cell line and treatment. Scale bar = 20 μm. Arrow = apoptotic nuclei. B. Average percentage of
structures expressing basal β4 integrin were quantified for n = 3 biological replicates. Two-way ANOVA for all cell lines and treatments was
significant (p < 0.001). Bonferroni post test compared differences between control and treatment for each cell line, **p < 0.001.
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tures maintained basal expression of both β4 and α6
integrin after TGFβ treatment (Figures 7 and 8, respect-
ively). Of note, SB-431542 treatment significantly in-
creased the percent of Par6/wt cells expressing basal β4
and α6 integrin to levels similar to those observed in
Parental and Par6/S345A 3D structures under basal
conditions (Figures 7 and 8). All together, these results
indicate that the change in integrin localization in
NMuMG 3D structures is dependent on activation of
both TβRI and the Par6 pathway.Assessment of the cell survival mediator NF-κB and its
potential role in apoptosis downstream of the
TGFβ-Par6 pathway
NF-κB signaling has been shown to promote cell sur-
vival downstream of α6β4 integrin ligation in polarized
structures of mammary epithelial cells exposed to a var-
iety of apoptotic stimuli [22]. Since NMuMG cells dis-
play proper distribution of a number of markers of
apico-basal polarity in monolayer [17] as well as 3D cul-
tures [18], we used monolayer cultures to investigate
whether NF-κB mediates apoptotic resistance of Par6/
Figure 8 Par6 and TGFβRI activation mediate TGFβ-induced loss of basal α6 integrin expression in NMuMG 3D structures. 12-day old
3D cultures of the indicated NMuMG-derived cell lines were treated with control media (DMSO alone), TGFβ1 (TGFβ), the TβRI/Smad2 inhibitor
SB-431542 (SB) or TGFβ + SB for 48 hours, fixed and immunostained for α6 integrin (green). Dapi was used to visualize the nuclei (blue). A. Confocal
images show representative structures for each given cell line and treatment. Scale bar = 20 μm. Arrow= apoptotic nuclei. B. Average percentage of
structures expressing basal α6 integrin were quantified for n = 3 biological replicates. Two-way ANOVA for all cell lines and treatments was significant
(p < 0.01). Bonferroni post test compared differences between control and treatment for each cell line, *p < 0.05, **p < 0.001.
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TGFβ. At this time point, these cells do not downregulate
β4 integrin expression and maintain basal localization of
integrin α6β4, while the opposite is true for the apoptosis-
sensitive Parental and Par6/wt cells.
We first examined the phosphorylation status of p65/
RelA (an essential component of the NF-κB complex) at
Serine 536 (S536), which has been reported to be important
for NF-κB transcriptional activity [31]. A decrease in p65/
RelA phosphorylation, which paralleled a decrease in total
p65/RelA level, was observed in parental and Par6/wt cells
after both 48 and 144 hours of TGFβ exposure (Figure 9A,
C). However, quantification of p65/RelA phosphorylationshowed a significant TGFβ-induced decrease only in Par6/
wt cells at the 144 hours time point (Figure 9B,D). In con-
trast, in response to TGFβ treatment, Par6/S345A cells
showed a trend toward increased p65/RelA S536 phosphor-
ylation, while phosphorylation at the same site remained
relatively unchanged in β4 null cells at both time points
(Figure 9B,D). In all TGFβ-treated cells, SB-431542 treat-
ment restored phosphorylated p65/RelA to levels similar or
slightly lower to those observed with SB-431542 treatment
alone at both time points (Figure 9B,D). This suggest that
changes in p65/RelA phosphorylation are dependent on
both Par6 and TβRI activation, but in cells with an over-
active Par6 pathway exposure to TGFβ over prolonged
Figure 9 TGFβ-induced changes in p65/RelA phosphorylation are dependent on Par6 and TβRI activation. Subconfluent monolayers of
the indicated NMuMG-derived cell lines were treated for 48 (A, B) or 144 (C, D) hours with control media (DMSO alone), TGFβ1 (TGFβ, 5 ng/ml),
the TβRI inhibitor SB-431542 (SB, 10 μM) or TGFβ + SB. The level of phosphorylated p65/RelA (pRelA, S536), native p65/RelA and α-tubulin
(loading control) was examined by immunoblotting. Graphs in B and D represent the average relative p65/RelA phosphorylation at S536 as determined by
band densitometry for 3 independent experiments. Relative p65/RelA phosphorylation was calculated as the ratio of phosphorylated p65/RelA to
native p65/RelA. The value for DMSO control was set to 1 for each cell line. Two-way ANOVA for all cell lines and treatments was significant (p < 0.01)
only for the 144-hour treatment. Bonferroni post test compared differences between control and treatment for each cell line, *p < 0.05, **p < 0.001.
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http://www.cancerci.com/content/14/1/19periods of time results in significant down-regulation of
p65/RelA phosphorylation independent from TβRI activa-
tion (Figure 9D). Further, TβRI activation has a promoting
rather than inhibiting effect on p65/RelA phosphorylation
under the examined conditions.
Since p65/RelA transcriptional activity is known to de-
pend on nuclear translocation [32], next we examined its
localization after 48-hour TGFβ stimulation using IF im-
aging. We chose to analyze 48-hour treated cell mono-
layers, because TGFβ-induced changes in the level of native
and phosphorylated p65/RelA, which paralleled apoptotic
response in both parental and Par6/wt cells, were seen in
whole lysates obtained from monolayer cell cultures at the
48-hour time point. p65/RelA localization was always cyto-
plasmic and no change in this localization was observed in
any of the aforementioned cell lines upon TGFβ exposure
(Figure 10), suggesting that a reduction in NF-κB transcrip-
tional activity does not mediate TGFβ pro-apoptotic effect
on NMuMG cell monolayers, at least at this time point.
Discussion
The TGFβ-Par6 pathway was initially reported to be re-
quired for the loss of the TJ and TGFβ-induced EMT inFigure 10 NMuMG monolayers do not re-localize p65/RelA in respons
indicated NMuMG-derived cell lines were treated for 48 hours with control
TGFβ + SB. Cells were then fixed and p65/RelA expression/localization (gre
nuclei (blue). Images are representative of two independent experiments, SNMuMG cells [17]. We have previously demonstrated
the role of this pathway in invasiveness and metastasis
of breast cancer cells [18], when we also observed that
blockade of Par6 activation abrogates TGFβ-induced loss
of polarity of acini-like structures of NMuMG and inhibits
TGFβ-induced apoptosis [18]. By comparing caspase-3
and -9 activation in NMuMG cells with active or inactive
Par6 and TGFβ/Activin signaling pathways, this study val-
idates our previous findings [18] and provides new in-
sights on the interplay between Par6 and TβRI activation
in determining mammary cell apoptotic response to long
or short-term TGFβ exposure.
The similar capacity of the dominant negative Par6/
S345A mutant to block TGFβ-induced apoptosis in 2D
(monolayer) as well as 3D cultures on rBM indicates
that this phenomenon is not restricted to acini-like
structures, and the effect of both Par6 and TβRI inhib-
ition in blocking TGFβ-induced apoptosis supports the
notion that activation of both TβRI and Par6 is required
for apoptosis to occur. These findings are in agreement
with the demonstrated role of TβRI in recruiting and acti-
vating Smad2/3 and TRAF6 to signal apoptosis [19-21,33].
With regard to Par6, they suggest a potential link betweene to 48-hour TGFβ treatment. Subconfluent monolayers of the
media (DMSO alone), TGFβ1, the TβRI inhibitor SB-431542 (SB) or
en) was detected by immunofluorescence. Dapi was used to visualize
cale bar = 20 μm.
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tosis, which has also been supported by previous studies.
For instance, treatment of prostate cancer cells with aur-
othiomalate was shown to disrupt the PKCι/Par6 complex,
leading to caspase-3 activation and apoptosis [34]. Si-
milarly, radiation-induced injury was shown to promote
apoptosis via disruption of the Cdc42/Par6/atypical pro-
tein kinase C Par polarity complex that localizes to the TJ
[35], and Par3 knockout and consequent withdrawal from
the Par complex promoted apoptosis in keratinocytes [36].
Taken together, these and our observations suggest that
perturbations of the Par complex and the TJ leads to
apoptosis. The possible disruptive effect of Par6 phosphor-
ylation on Par6’s interaction with other members of the
Par complex has yet to be determined and could poten-
tially explain the positive impact of Par6 activation on
TGFβ-induced apoptosis.
The connection between apico-basal polarity and cell
survival has also been reported. Weaver et al. demon-
strated that polarized acini-like structures of mammary
epithelial cells are resistant to a variety of apoptosis-
inducing stimuli [22], supporting the notion that loss of
polarity might be a pre-requisite for cells to undergo
apoptosis. This and further studies by the Weaver’s
group reiterated the importance of α6β4 integrin and
NF-κB signaling in driving survival of both normal and
transformed mammary epithelial cells [22,24]. This evi-
dence prompted us to investigate the potential connec-
tion between activation of the Par6 pathway, α6β4
integrin expression/localization and NF-κB signaling in
the context of TGFβ-induced apoptosis. Apart from our
previous findings pointing to the requirement of Par6
signal for apoptotic response to TGFβ [18], we were in-
trigued by the high apoptosis rate shown by an empty
vector-expressing NMuMG cell variant previously gener-
ated by the Wrana group [17], which failed to form
acini-like structures on rBM and had very high levels of
basal apoptosis (Ozdamar and Viloria-Petit et al., unpub-
lished observations and Figure 3). Here we show that
these cells lack expression of β4 integrin, express signifi-
cantly lower basal levels of E-cadherin and display in-
creased Smad activation in response to TGFβ, a group
of features that correlate with their inability to form po-
larized acini-like structures and with their high apoptosis
rate in both monolayer and 3D culture. Further, despite
of their high basal apoptosis and high Smad activation in
response to TGFβ, these cells have reduced apoptotic re-
sponse to this growth factor. Taken together, these results
indicate a potential link between β4 integrin-mediated
apico-basal polarity, TGFβ signaling and apoptosis.
We found that TGFβ1 stimulation for 48 hours reduces
expression of β4 integrin, and disrupts basal localization
of α6β4 integrin in 3D structures of NMuMG cells. Be-
cause these effects were not seen in cells with an inactivePar6 pathway or Parental cells treated with a TβRI inhibi-
tor, both of which maintained ZO-1 and E-cadherin ex-
pression, these results suggest that the modulation of
α6β4 integrin by TGFβ requires both activation of Par6
and of TβRI, and that the activity of these two signaling
effectors is also essential for loss of polarity. Our results
are also in agreement with a previous report showing that
TGFβ downregulates β4 integrin expression in mammary
epithelial cells [37].
Although we were not able to detect changes in p65/
RelA localization in response to TGFβ stimulation for
48 hours, we observed a reduction in p65/RelA expres-
sion and concomitant downregulation of p65/RelA phos-
phorylation that was rescued by TβRI inhibition in both
Parental and Par6/wt cells. This effect was more pro-
nounced at the 144-hour time point, when it became
statistically significant and independent of TβRI activa-
tion only for Par6/wt cells. Because TGFβ was not able
to downregulate p65/RelA phosphorylation in β4 null
cells our results suggest that TGFβ’s impact on p65/RelA
phosphorylation may require β4 integrin expression.
Based on the contrasting increase in phospho-p65/RelA
observed in Par6/S345A in response to TGFβ, and the
capacity of the TβRI inhibitor to block this increase as
well, we speculate that TβRI activation, which is more
prominent when the S345 phosphorylation site on Par6
is blocked [18] (see also pSmad2 level as a read-out of
TβRI activity in Figure 6A and B), promotes p65/RelA
phosphorylation. Consequently, it is probable that the
donwregulation of phospho-p65/RelA seen in Par6/wt
cells at the 6-day time point is the result of prolonged
preferential activation of Par6 over TβRI. Therefore, the
balance between Par6 and TβRI activation might be key
in modulating the activation status of signaling pathways
downstream of the TGFβ receptors and hence the cellu-
lar effects of TGFβ.
Given that prolonged (144-hour) exposure to TGFβ
results in significant changes in p65/RelA phosphoryl-
ation in Par6/wt cells, the only cells that undergo signifi-
cant apoptosis at this time point, it is still possible that
negative modulation of NF-κB signaling in Par6/wt cells
plays a role in the higher apoptotic response of these
cells to long-term TGFβ exposure. Thus, more extensive
studies looking at NF-κB localization, NF-κB-dependent
promoter activity and expression of target genes upon
short- and long-term exposure to TGFβ are necessary to
ultimately establish or rule-out the involvement of this
transcription factor in TGFβ-induced apoptosis, particu-
larly in the context of Par6 activation.
Conclusions
In summary, here we show that Par6 and TβRI activation
are both necessary for TGFβ-induced apoptosis in NMuMG
cells. Par6 overactivation significantly enhances NMuMG
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prolonged exposure to this growth factor in monolayer
culture, when NMuMG parental cells are usually insensi-
tive to TGFβ’s pro-apoptotic effect. Given that TβRI acti-
vation in Par6/wt expressing cells under these conditions
appears significantly reduced (judging by the level of Smad
activation), this suggests that a high ratio of Par6 to TβRI
activation upon long-term TGFβ exposure can revert
NMuMG from apoptosis resistant to apoptosis sensitive.
Both Par6 and TβRI signaling are required for loss of ap-
ical basal polarity and for the reduction in β4 integrin ex-
pression, loss of basal localization of integrin α6β4, and
downregulation of NF-κB p65/RelA expression in re-
sponse to 48-hour stimulation with TGFβ. Of note,
long-term TGFβ exposure (144 hours) results in signifi-
cant reduction in p65/RelA phosphorylation via Par6
activation in contrast to increased p65/RelA phosphor-
ylation via TβRI activation. Establishing the contribu-
tion of NF-κB and other mediators of cell survival
signaling to TGFβ’s capacity to induce apoptosis might
prove useful in stratifying breast cancer patients for
conventional or molecular-targeted therapy. In this re-
gard, it will be important to determine whether in those
advanced breast cancers that display active TGFβ signal-
ing, higher endogenous Par6 levels correlate with better
patient prognosis due to enhanced TGFβ-dependent
tumor suppression and/or improved therapy response.
Methods
Antibodies, growth factors, and inhibitors
Antibodies included: β1 integrin (#610167), β4 integrin
(#553745), α6 integrin (#555734) (all from BD Biosci-
ences); Smad2 (#3103), phospho-Smad2 (S465/467, #3
101), NF-κB p65 (#4764), phospho-NF-κB p65 (S536, #30
33), E-cadherin (#4065), β-actin (#4967), Caspase-3
(#9662), Cleaved Caspase-3 (#9661), Cleaved Caspase-9
(#9509), cleaved PARP (#9544) (all from Cell Signaling),
α-tubulin (#T5168, Sigma-Aldrich), ZO-1 (#sc-33725,
Santa Cruz), and Alexa-Fluor®-conjugated secondary anti-
bodies (Molecular Probes®, Life Technologies). Growth
factors/hormones included: rhTGFβ1 (Invitrogen) and in-
sulin (Sigma-Aldrich). The TβRI inhibitor SB-431542 was
from InvivoGen.
Cell lines and culture conditions
NMuMG parental cells (ATCC) were grown in high glu-
cose DMEM (HyClone) supplemented with 10% FBS
and 10 μg/ml insulin. NMuMG cells expressing Pmep5
(Vector), Pmep5-mPar6 (Par6/wt), or Pmep5-mPar6
mutant S345A (Par6/S345A) (a generous gift from Dr. J.
Wrana, SLRI, Toronto, ON) were previously gener-
ated [17] and grown in DMEM high glucose supple-
mented with 10% FBS, 10 μg/ml insulin, and 500 μg/
ml G418. All cells were maintained in a humidifiedincubator at 37°C in the presence of 5% CO2 and 95%
atmospheric air.
Matrigel 3D cultures and immunofluorescence staining
NMuMG cells were maintained under standard culture
conditions as aforementioned. Subconfluent monolayers
were trypsinized in a solution of 0.05% Trypsin/0.53 mM
EDTA (Invitrogen), washed once with DMEM plus 10%
FBS, resuspended in assay media, and plated as a single
cell suspensions on 100% growth factor reduced Matrigel
(BD Biosciences) using the overlay method as previously
described [18]. Assay media contained 2% Matrigel added
to mammary epithelial growth media supplemented with
0.4% bovine pituitary extract, 10 ng/ml epidermal growth
factor (EGF), 5 μg/ml insulin and 0.5 μg/ml hydrocorti-
sone, according to manufacturer’s instructions (Pro-
moCell). Medium was changed every 3 days. 5 ng/ml
recombinant human TGFβ1 and/or 10 μM of the TGFβ
receptor I inhibitor SB-431542 was added after mature
structures were formed (12-15 days after cell plating)
and replenished every 2 days. Immunofluorescence (IF)
was performed as previously described [18]. Briefly, 3D
cultures on 4-well glass chamber slides (BD Biosciences)
were washed twice with ice-cold PBS, after which cul-
tures were fixed with 4% Paraformaldehyde (EMS) in
PBS for 20 minutes at room temperature. The fixed cul-
tures were then washed with PBS and permeabilized
with cold 0.5% Triton-X (Bio-Rad) in PBS for 10 mi-
nutes, followed by four washes with 100 mM Glycine
(Fisher) in PBS. Permeabilized cultures were blocked for
one hour at room temperature using 10% goat serum di-
luted in IF buffer, which consisted of 0.1% BSA (Santa
Cruz), 0.2% Triton-X (Bio-Rad), and 0.05% Tween-20
(Bio-Rad) dissolved in PBS. Fixed cultures were next in-
cubated with primary antibody diluted in blocking solu-
tion overnight (final dilutions as recommended by
manufacturer). Next day, 3D structures were washed
three times in IF buffer and then incubated with Alexa
Fluor® secondary antibodies (Life Technologies; final di-
lution 10 μg/ml). Following incubation with secondary
antibody, cultures were washed three times in IF buffer,
followed by a ten-minute incubation with 0.3 μM 4′,
6′-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich)
in PBS. The chambers were then removed, and slides
were mounted with coverslips using Prolong Gold®
(Promega) to preserve the fluorescence. All slides were
analyzed using an Olympus FV500 confocal microscope
(Olympus). Images were captured using Fluoview 5.0
software (Olympus).
Treatment and western blotting
For analysis of protein expression, confluent (to be used
for 2 day treatment) or sub-confluent (to be used for
6 day treatment) cells were serum starved with reduced
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2 hours, which was then changed to the reduced serum
medium containing TGFβ1 (5 ng/ml) and/or the SB-
431542 inhibitor (10 μM). Medium was changed every
2 days. Cells were lysed with protein lysis buffer (20 mM
Tris-HCl, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA,
1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin)
(Cell Signaling) supplemented with 1 mM PMSF (Sigma-
Aldrich), 2 μg/ml aprotinin (Sigma-Aldrich), 1 mM
Na3VO4 (New England Biolabs), and 1% phosphatase in-
hibitor cocktail 2 (Sigma-Aldrich). Protein samples were
resolved on 7.5%, 10%, or 12% polyacrylamide (Bio-Rad)
gels and then transferred to a PVDF membrane (Roche),
washed twice with Tris Buffered Saline plus 0.05% Tween
(TBS-T) and then blocked for one hour with either 5%
milk in TBS-T or 5% BSA (to detect phosphorylated pro-
teins) in TBS-T. Membranes were incubated with primary
antibody diluted in blocking solution overnight (final di-
lution as recommended by manufacturer, except for
pSmad2, used 1:500; Smad2, used 1:5,000; and αTubu-
lin, used 1:160,000). Next day, membranes were washed
3 times per 10 min with TBS-T, and then incubated with
either 1:10,000 goat anti-mouse HRP, 1:10,000 mouse
anti-rabbit HRP (Both Sigma-Aldrich), or 1:1,000 goat
anti-rat HRP (Millipore) diluted in 5% milk in TBS-T
for 1 hour at room temperature. Membranes were then
washed 3-6 times per 10 min in TBS-T following sec-
ondary antibody incubation. Immunoglobulin-antigen
complexes were incubated with a chemiluminescence
detection system (Roche) for 1 min and subsequently
exposed to X-ray film (Kodak) or to a Chemidoc™ MP
Image System (Bio-Rad). Protein bands from film were
quantified using a FluorChem 9900 imaging system
(Alpha Immunotech), while images captured with Chemidoc
MP were quantified using Image Lab software (Bio-Rad).
Protein loading was normalized using bands for α-tubulin.
Relative phosphorylation levels were normalized to native
protein bands.
Quantitative real-time PCR (qRT-PCR)
RNA was isolated from cultured cells by homogenization
in Trizol at cold temperature followed by the Aurum
total isolation RNA kit (Bio-Rad). cDNA synthesis was
performed using the iScript cDNA synthesis kit (Bio-Rad)
with 1 μg total RNA. Appropriate quality control steps
were included along the way conforming to the MIQE
guidelines [38,39]. The cDNA that was obtained was di-
luted 1:4 in nuclease free water and 4 μl of diluted cDNA
was added to reaction mixes (10 μl) containing 5 μl Sso
Fast Eva Green Supermix (Bio-Rad) and 500 nM of each
primer. Primer sequences were obtained from the Harvard
primer bank: mouse GAPDH F 5-cacaccgaccttcaccatttt-3;
mouse GAPDH R 5-gagacagccgcatcttcttgt-3; mouse β4 F5-aggcctgagaacagaggtca-3; mouse β4 R 5-ccggagatgcacat
tgtatg-3. Primers were optimized using a temperature gra-
dient and eight point standard curve to determine PCR ef-
ficiency. Acceptable efficiency was deemed between 90%
and 110%. qRT-PCR amplifications were carried out using
a CFX-96 (Bio-Rad) as follows: an initial denaturation step
2 minutes at 95°C, followed by 40 cycles of 5 seconds at
95°C and 5 seconds at 59°C. Data was expressed as relative
gene expression normalized to GAPDH mRNA, which
was determined to be a suitable housekeeping gene using
qBase Plus software (BioGazelle).Evaluation of cell death and integrin localization in
3D cultures
Apoptotic cells were detected by IF staining with cleaved
caspase-3 or cleaved caspase-9 (Cell Signaling) anti-
bodies. Integrin localization was assessed by IF staining
for α6 and β4 integrin. Results were quantified as per-
cent of apoptotic structures or percentage of structures
expressing basal α6 or β4 integrin. 3-10 low power (20×)
confocal images, or the equivalent to at least 100 structures,
were analyzed per group and condition for each experiment.Statistical analysis
Means were calculated and plotted along with standard
error bars. All statistical analyses were done using Graph-
Pad Prism software version 3.1 (GraphPad). Data were
first analyzed by two-way ANOVA. Significant differences
between means were subsequently determined using the
Bonferroni post-tests and were considered statistically
significant when the p value was less than 0.05. Three
biological replicates were included for all experiments,
with the exception of cleaved PARP western blotting
and cleaved caspase-3 IF, which were tested in two and
one independent experiments, respectively. qRT-PCR
experiments additionally included three technical repli-
cates per run.
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